Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tg Therapeutics (NQ: TGTX )

20.04 +0.05 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,639,075
Open 20.48
Bid (Size) 20.05 (5)
Ask (Size) 20.10 (4)
Prev. Close 19.99
Today's Range 19.44 - 20.79
52wk Range 6.460 - 23.12
Shares Outstanding 150,977,564
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities

Performance

YTD
+17.61%
+17.61%
1 Month
+0.65%
+0.65%
3 Month
+18.44%
+18.44%
6 Month
+36.89%
+36.89%
1 Year
+107.02%
+107.02%

More News

Read More
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
TGTX Stock Earnings: TG Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
(TGTX) - Analyzing TG Therapeutics's Short Interest
Via Benzinga
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%
Via Investor's Business Daily
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Via Chartmill
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Via The Motley Fool
Nasdaq 100 Overbought? Here’s What History Says About The Current Rally
Via Talk Markets
The Most Shorted Stocks in June: Hold, Short, or Squeeze?
Via MarketBeat
Peering Into TG Therapeutics's Recent Short Interest
Via Benzinga
(TGTX) - Analyzing TG Therapeutics's Short Interest
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Via FinancialNewsMedia
Exposures Product Safety
Why TG Therapeutics Stock Was Rocketing Higher This Week
Via The Motley Fool
TGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
TG Therapeutics stock just rallied 30%: what happened?
Via Talk Markets
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is Multiple Sclerosis-Focused TG Therapeutics Stock Trading Higher Today?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
Via Investor's Business Daily
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.